Modified XELIRI Noninferior to FOLFIRI for Metastatic CRC

mXELIRI could be practice-changing by providing an alternative to irinotecan-based regimens for some patients, but may not work in non-Asian populations.

Source: CancerNetwork - April 13, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Colorectal Cancer News Source Type: news